Evidence map›Paper›PMID 24327950›Full record

ReviewMolecular metabolism2013

Genetic and epigenetic control of metabolic health.

Robert Wolfgang Schwenk, Heike Vogel, Annette Schürmann

Open access · goldAbstract readReview
In one paragraph

Review in Molecular metabolism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Exploring genetic loci of type 2 diabetes and cancer: a review.Endocrine oncology (Bristol, England) · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Robert Wolfgang Schwenk
Heike Vogel
Annette Schürmann

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is characterized as an excess accumulation of body fat resulting from a positive energy balance. It is the major risk factor for type 2 diabetes (T2D). The evidence for familial aggregation of obesity and its associated metabolic diseases is substantial. To date, about 150 genetic loci identified in genome-wide association studies (GWAS) are linked with obesity and T2D, each accounting for only a small proportion of the predicted heritability. However, the percentage of overall trait variance explained by these associated loci is modest (~5-10% for T2D, ~2% for BMI). The lack of powerful genetic associations suggests that heritability is not entirely attributable to gene variations. Some of the familial aggregation as well as many of the effects of environmental exposures, may reflect epigenetic processes. This review summarizes our current knowledge on the genetic basis to individual risk of obesity and T2D, and explores the potential role of epigenetic contribution.

Indexed as

ADCY3, adenylate cyclase 3AQP9, aquaporin 9BDNF, brain-derived neurotrophic factorCDKAL1, CDK5 regulatory subunit associated protein 1-like 1CPEB4, cytoplasmic polyadenylation element binding protein 4DUSP22, dual specificity phosphatase 22DUSP8, dual specificity phosphatase 8EpigeneticsGALNT10, UDP-N-acetyl-alpha-d-galactosamine:polypeptide N-acetylgalactosaminyltransferase 10 (GalNAc-T10)GIPR, gastric inhibitory polypeptide receptorGNPDA2, glucosamine-6-phosphate deaminase 2GP2, glycoprotein 2 (zymogen granule membrane)GWASHIPK3, homeodomain interacting protein kinase 3IFI16, interferon, gamma-inducible protein 16KCNQ1, potassium voltage-gated channel, KQT-like subfamily, member 1KLHL32, kelch-like family member 32LEPR, leptin receptorMAP2K4, mitogen-activated protein kinase kinase 4MAP2K5, mitogen-activated protein kinase kinase 5MIR148A, microRNA 148aMMP9, matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase)MNDA, myeloid cell nuclear differentiation antigenNFE2L3, nuclear factor, erythroid 2-like 3ObesityPACS1, phosphofurin acidic cluster sorting protein 1PAX6, paired box gene 6PCSK1, proprotein convertase subtilisin/kexin type 1PGC1α, peroxisome proliferative activated receptor, gamma, coactivator 1 alpha, PM2OD1Positional cloningPRKCH, protein kinase C, etaPRKD1, protein kinase D1PRKG1, protein kinase, cGMP-dependent, type IQPCTL, glutaminyl-peptide cyclotransferase-likeRBJ, DnaJ (Hsp40) homolog, subfamily C, member 27RFC5, replication factor C (activator 1) 5RMST, rhabdomyosarcoma 2 associated transcript (non-protein coding)SEC16B, SEC16 homolog BTFAP2B, transcription factor AP-2 beta (activating enhancer binding protein 2 beta)TNNI3, troponin I type 3 (cardiac)TNNT1, troponin T type 1 (skeletal, slow)Type 2 diabetes

Identifiers

PMID24327950
PMCPMC3854991
OpenAlexW2152196964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.